PEAK6’s Neumora Therapeutics NMRA Stock Holding History

PEAK6’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-56,300	Closed	-$102K	–	3205
2025 Q3	$102K	Buy	+56,300	New	+$91K	﹤0.01%	2598

Other funds holding NMRA

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

PEAK6's NMRA Position: Q1 2025 in Review

PEAK6 sold out of Neumora Therapeutics (NMRA) in Q1 2025, closing a stake of 11,057 shares — an estimated $117K sold.

PEAK6 first reported a position in NMRA in Q4 2024 and held it in 1 quarter. The position peaked at $117K in Q4 2024. 115 funds tracked by Wall St. Rank hold NMRA as of Q1 2025.

PEAK6 reported no remaining Neumora Therapeutics position as of Q1 2025 after selling out during the quarter.
PEAK6 sold 11,057 Neumora Therapeutics shares in Q1 2025, an estimated $117K.
PEAK6 first reported a position in Neumora Therapeutics in Q4 2024 and held it in 1 quarter.
PEAK6's Neumora Therapeutics position peaked at $117K in Q4 2024.
115 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2025.

Based on PEAK6's 13F filing for Q1 2025, filed 14 May 2025.